Episode 2: Establishing the Evidence: Clinical Trials with TNF Inhibitors

Biologic Therapy In Rheumatoid Arthritis

Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination therapy of a TNF-alpha agent and methotrexate results in highly significant improvement in arthritic symptoms and signs.